Secondary neutrons in clinical proton radiotherapy: a charged issue
- PMID: 18192046
- DOI: 10.1016/j.radonc.2007.12.003
Secondary neutrons in clinical proton radiotherapy: a charged issue
Abstract
Hospital-based proton facilities may represent a major advance in radiation therapy, in part because of excellent dose distributions around the tumor, and in part because of the potentially lower whole-body dose compared with photon radiotherapy. Most current proton beams are spread out to cover the tumor using beam scattering and collimation techniques (passive scattering); this will necessarily result in an extra whole-body neutron dose, due to interactions of the protons with the scattering and collimating beam elements. However, the clinical significance of this whole-body low-dose neutron exposure has remained controversial. The number of proton facilities worldwide is increasing rapidly, and most of these facilities are/will be based on passive scattering. Thus it is important to assess and, ideally, minimize, the potential for second cancer induction by secondary neutrons. We discuss here the neutron doses involved, and the associated potential second cancer risks, with an emphasis on the uncertainties involved.
Similar articles
-
Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.Radiother Oncol. 2008 Feb;86(2):148-53. doi: 10.1016/j.radonc.2007.12.024. Epub 2008 Jan 30. Radiother Oncol. 2008. PMID: 18237800
-
Intensity-modulated radiation therapy, protons, and the risk of second cancers.Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7. doi: 10.1016/j.ijrobp.2006.01.027. Int J Radiat Oncol Biol Phys. 2006. PMID: 16618572 Review.
-
Secondary neutron doses for several beam configurations for proton therapy.Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):260-5. doi: 10.1016/j.ijrobp.2008.10.090. Int J Radiat Oncol Biol Phys. 2009. PMID: 19362245
-
Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age.Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):228-35. doi: 10.1016/j.ijrobp.2008.04.069. Epub 2008 Jun 18. Int J Radiat Oncol Biol Phys. 2008. PMID: 18571337
-
Modelling carcinogenesis after radiotherapy using Poisson statistics: implications for IMRT, protons and ions.J Radiol Prot. 2009 Jun;29(2A):A143-57. doi: 10.1088/0952-4746/29/2A/S10. Epub 2009 May 19. J Radiol Prot. 2009. PMID: 19454805 Review.
Cited by
-
The Pediatric Proton and Photon Therapy Comparison Cohort: Study Design for a Multicenter Retrospective Cohort to Investigate Subsequent Cancers After Pediatric Radiation Therapy.Adv Radiat Oncol. 2023 May 21;8(6):101273. doi: 10.1016/j.adro.2023.101273. eCollection 2023 Nov-Dec. Adv Radiat Oncol. 2023. PMID: 38047226 Free PMC article.
-
Simultaneous induction of dispersed and clustered DNA lesions compromises DNA damage response in human peripheral blood lymphocytes.PLoS One. 2018 Oct 31;13(10):e0204068. doi: 10.1371/journal.pone.0204068. eCollection 2018. PLoS One. 2018. PMID: 30379881 Free PMC article.
-
Reduction of the secondary neutron dose in passively scattered proton radiotherapy, using an optimized pre-collimator/collimator.Phys Med Biol. 2009 Oct 21;54(20):6065-78. doi: 10.1088/0031-9155/54/20/003. Epub 2009 Sep 24. Phys Med Biol. 2009. PMID: 19779218 Free PMC article.
-
Design of a focused collimator for proton therapy spot scanning using Monte Carlo methods.Med Phys. 2020 Jul;47(7):2725-2734. doi: 10.1002/mp.14139. Epub 2020 Apr 6. Med Phys. 2020. PMID: 32170750 Free PMC article.
-
Assessing the risk of second malignancies after modern radiotherapy.Nat Rev Cancer. 2011 Jun;11(6):438-48. doi: 10.1038/nrc3069. Epub 2011 May 19. Nat Rev Cancer. 2011. PMID: 21593785 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources